Market closedADR
Zai Lab/$ZLAB
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Zai Lab
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-2306 for treatments across multiple solid tumor types including ovarian and certain types of breast and lung cancers; ZL-2401 which is an antibiotic in a new class of tetracycline derivatives; and ZL-2301 is an oral, small molecule which targets HCC.
Ticker
$ZLAB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
2,175
Website
Zai Lab Metrics
BasicAdvanced
$3.7B
-
-$2.78
0.98
-
Price and volume
Market cap
$3.7B
Beta
0.98
52-week high
$33.00
52-week low
$13.48
Average daily volume
698K
Financial strength
Current ratio
3.006
Quick ratio
2.394
Long term debt to equity
0.916
Total debt to equity
18.825
Interest coverage (TTM)
-250.52%
Management effectiveness
Return on assets (TTM)
-20.84%
Return on equity (TTM)
-34.98%
Valuation
Price to revenue (TTM)
9.261
Price to book
4.98
Price to tangible book (TTM)
5.42
Price to free cash flow (TTM)
-15.069
Growth
Revenue change (TTM)
35.01%
Earnings per share change (TTM)
-11.07%
3-year revenue growth (CAGR)
45.61%
3-year earnings per share growth (CAGR)
-23.71%
What the Analysts think about Zai Lab
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Zai Lab stock.
Zai Lab Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Zai Lab Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Zai Lab News
AllArticlesVideos
Zai Lab Receives Orphan Drug Designation from the U.S. FDA for ZL-1310 (DLL3 ADC) for the Treatment of Small Cell Lung Cancer (SCLC)
Business Wire·1 month ago
Zai Lab Announces Acceptance of New Drug Application for KarXT for the Treatment of Schizophrenia
Business Wire·1 month ago
Zai Lab Announces Positive Topline Results for TIVDAK in the China Subpopulation of the Global Phase 3 innovaTV 301 Trial in Patients with Recurrent or Metastatic Cervical Cancer
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Zai Lab stock?
Zai Lab (ZLAB) has a market cap of $3.7B as of February 23, 2025.
What is the P/E ratio for Zai Lab stock?
The price to earnings (P/E) ratio for Zai Lab (ZLAB) stock is 0 as of February 23, 2025.
Does Zai Lab stock pay dividends?
No, Zai Lab (ZLAB) stock does not pay dividends to its shareholders as of February 23, 2025.
When is the next Zai Lab dividend payment date?
Zai Lab (ZLAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Zai Lab?
Zai Lab (ZLAB) has a beta rating of 0.98. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.